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The pharmacokinetic characteristics of cefonicid, a highly protein-bound expanded-spectrum cephalosporin,
were examined in six noninfected, clinically stable patients undergoing continuous ambulatory peritoneal
dialysis. After a 1.0-g intravenous dose of cefonicid, the mean concentrations in serum were 105 + 25 and 35.6
± 14.4 ,ug/ml at 3 and 72 h, respectively. Despite a prolonged half-life in serum of 49.7 ± 18 h, the penetration
into peritoneal fluid was low. The average concentration in dialysate over the 72-h study period was 2.7 ,Ig/ml.
The serum clearance was 2.6 ± 1.0 ml/min, and the distribution volume was 0.14 ± 0.02 liter/kg. Dosage
recommendations and clinical considerations for cefonicid use in continuous ambulatory peritoneal dialysis
patients are discussed.
Bacterial peritonitis predominantly caused by staphylo-
coccal species is a frequent complication of continuous
ambulatory peritoneal dialysis (CAPD). Cephalosporins are
commonly prescribed for the treatment of this complication.
Antibiotics which can be administered on an infrequent basis
are desirable to avoid hospitalization and simplify the treat-
ment regimen for the convenience of the patient. In addition,
an antibiotic which does not require administration in every
dialysis exchange would decrease potential contamination
caused by repeated admixture with dialysate fluid (11).
Cefonicid is a long-acting cephalosporin with a half-life in
serum of 3.5 to 4.5 h in patients with normal renal function
(4, 8). The half-life is further prolonged as creatinine clear-
ance (CL) declines and has been noted to be as long as 70 h
when creatinine CL is less than 5 ml/min (3). The present
study was conducted to examine the pharmacokinetic char-
acteristics of cefonicid in CAPD patients and to evaluate its
potential for convenient intermittent intravenous therapy for
CAPD-related peritonitis.
MATERIALS AND METHODS
Six stable CAPD patients with no clinical signs or symp-
toms of peritonitis were admitted to the study after informed
consent was obtained. Patients were excluded if they had
previous beta-lactam allergy, antibiotic therapy within the
past 2 weeks, severe cardiac (clinical congestive failure) or
hepatic (twice normal serum levels of alanine transferase,
aspartate aminotransferase, or both) dysfunction, or abnor-
mal coagulation (prothrombin time or partial thromboplastin
time of 5 s greater than control) parameters.
An indwelling venous catheter was placed in the arm
contralateral to the infusion site, and a 1.0-g dose of
cefonicid was administered over 8 min. Blood samples were
obtained at 0, 3, 6 (end of first dialysis period), 9, 12 (end of
second dwell period), 24, 48, and 72 h. CAPD was continued
throughout the study period with q4h to q8h exchanges
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based on individual requirements. All dialysate drainage was
measured, and a sample was saved. Blood samples were
allowed to clot, and then serum was obtained by centrifuga-
tion. Serum and dialysate samples were stored at -30°C
until assayed.
Analytical-grade cefonicid (Smith Kline & French Labo-
ratories, Philadelphia, Pa.) was measured by high-
performance liquid chromatography with a modification of a
previously reported assay (6). To 0.5 ml of sample (serum or
dialysate), 0.2 ml of internal standard (cefazolin) and 1 ml of
acetonitrile were added. The mixture was vortexed for 15 s,
shaken for 5 min, and centrifuged (1,200 x g; 5 min). To the
supernatant, 2 ml of methylene chloride was added, and the
mixture was vortexed, shaken, and centrifuged as described
above. A 20-pl quantity of the upper aqueous phase was
injected onto a Varian Micropak C-18 column (Varian Lab-
oratories, Walnut Creek, Calif.). A mobile phase of 1%
methanol in 2 M sodium acetate (pH 5.2) was run at a flow
rate of 1 ml/min, and cefonicid was monitored at 210 nm. The
intraday and interday relative standard deviation was less
than 7%.
Data on concentration in serum were entered into the
LAGRAN program (9) to determine the area under the
serum concentration versus time curve (AUC) and the serum
concentration x time versus time curve (area under the
moment curve, AUMC). Total CL, volume of distribution at
steady-state (V,s), and the serum half-life (t1/2) were deter-
mined as follows: CL = dose/AUC0', Vs, = I CL, t1/2 =
0.693/A, where dose is the administered dose, f is the mean
residence time (AUMC/AUC), and X is the slope of the
elimination phase. In addition, the ratio of the amount of
drug (XD) recovered via CAPD to the AUCO' was deter-
mined.
RESULTS
Cefonicid administration was well-tolerated by all of the
CAPD patients. A representative serum and dialysate con-
centration versus time profile is illustrated in Fig. 1.
Cefonicid concentrations in serum displayed a linear decline
over time, with mean values of 105 ± 25 ,ug/ml at 3 h, 73.3 ±
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TABLE 2. Individual cefonicid pharmacokinetic parameters in
CAPD patients after intravenous administration

























I Mean (SD) 0.04 (0.01) 0.14 (0.02) 49.6 (17.9) 0.24 (0.05)
72
Time, h
FIG. 1. Representative serum (0) and end-dialysate (A) concen-
tration versus time profile after a 1.0-g intravenous dose of
cefonicid. End-dialysate concentrations teflect accumulation of drug
throughout the dwell period.
19.2 [Lg/ml at 24 h, and 35.6 + 14.4. p.g/tl at 72 h. The mean
CL was 0.04 + 0.01 ml/min per 70 kg, and the mean V,, was
0.14 0.02 liter/kg. The serum t1/2 was 49.7 + 18 h.
Cefonicid diffused slowly into peritoneal fluid, with five of
six patients displaying less than 1 ,ug/ml at the end of the
initial dwell period. During subsequent dwell periods,
cefonicid attained mean end-dwell dialysate concentrations
of 4.1 ± 3.1 pzg/ml at 24 h, 2.3 ± 1.7 p.g/ml at 48 h, and 1.5
1.1 p.g/ml at 72 h. The mean XD:AUC value was 0.26
0.08 ml/min per 70 kg, and the mean percent of dose
recovered via CAPD was 6.5 ± 3.2%. Individual cefonicid
concentrations and pharmacokinetics are summarized in
Tables 1 and 2, respectively.
DISCUSSION
In comparison with the t1/2 of 3 to 4 h in normal humans,
the half-life of cefonicid in CAPD patients is markedly
prolonged to 50 h. This value is similar but somewhat lower
than that during hemodialysis, for which a t1/2 of 70 h has
been reported (3). The major factor which prolongs the
cefonicid t1/2 is the lack of a renal excretory route, upon
which this drug is heavily dependent for elimination. Serum
CL values of 25 ml/min in healthy subjects (3) far exceed the
low values found during CAPD in the present study (2.6
ml/min) and during hemodialysis (1.9 ml/min) (3). The vol-
ume of distribution of cefonicid in CAPD patients (0.14
liter/kg) is similar to that seen in hemodialysis patients,
chronic renal failure, and normal humans (3). Therefore, it is
apparent that the prolonged serum t1/2 is dtie to decreased
CL and not to changes in distribution volume.
Despite the prolonged serum t1/2 and the resultant eleva-
tion of concentrations in serum, concentrations in dialysate
were variable and generally low among the study patients.
The variability found for peritoneal drug concentrations is
consistent with the results of other studies that have found a
wide range of tissue-to-serum ratios in bone, uterine tissue,
gallbladder, wounds, pus, pleural fluid, and breast milk (5).
The cotncentrations of cefonicid in peritoneal fluid, however,
are lower than those reported in other tissue compartments.
This finding may reflect the more complex nature of the
peritoneai membrane and the numerous factors which affect
solute diffusion from serum into dialysate (7). Although not
studied in renal failure patients, the high degree of serum
protein binding of cefonicid in normal serum (98%) is a prime
factor which may contribute to slower diffusion into dialy-
sate (2). The low concentrations in dialysate are of some
concern, in that the MIC for 50% of Staphylococcus aureus
strains tested ranges from 2 to 4 jxg/ml and that for 50% of
Staphylococcus epidermidis strains tested ranges from 4 to 8
p.g/ml (1). Although the significance of achieving concentra-
tions in dialysate above the MIC for a specific pathogen
remains unclear, many CAPD centers advocate the contin-
uous intraperitoneal administration of antibiotics to over-
come subtherapeutic concentrations in dialysate (10). More
recently, the need for continuously adding cephalosporin
antibiotics to dialysate has been questioned and an alterna-
tive treatment regimen with a single daily intraperitoneal
dose has been suggested (11). In addition, antibiotic which is
present in dialysate is primarily unbound to protein (5a).
TABLE 1. Concentrations in serum and dialysate after intravenous administration of cefonicid to CAPD patients
Cefonicid concn (qg/ml)y at:
Patient no. 12 h 24 h 48 h 72 h
S D S D S D S D
1 86.5 4.5 77.4 2.9 51.1 1.8 32.0 NDb
2 109 ND 84.4 3.9 65.0 5.1 54.4 3.5
3 109 7.8 79.7 8.2 63.7 3.4 45.2 1.4
4 113 3.9 95.8 7.4 51.9 1.2 29.0 1.0
5 60.0 0.9 60.8 0.6 40.6 1.6 NCC 1.4
6 64.6 2.2 41.6 1.3 26.0 0.7 17.5 1.7
Mean (SD) 90.4 (23.7) 3.9 (2.6) 73.3 (19.2) 4.1 (3.1) 49.7 (14.7) 2.3 (1.7) 35.6 (14.4) 1.5 (1.1)
a S, Concentration in serum; D, concentration in dialysate.
b ND, Not detectable.
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Therefore, in the case of cefonicid, a concentration of 2
,Ig/ml in dialysate may be equivalent in activity to 100 ,ug/ml
in serum due to drug binding to albumin. Lastly, it is likely
that cefonicid concentrations would be greater in the pres-
ence of peritoneal inflammation.
In summary, cefonicid CL is markedly impaired during
CAPD. Concentrations in serum are elevated, but concen-
trations in dialysate are comparatively low after intravenous
administration. Factors other than the absolute drug concen-
tration in dialysate, such as host defenses, peritoneal tissue
drug concentration, and minimal dialysate protein binding,
may contribute to eradication of the infecting organism. It
would be worthwhile to examine the in vitro bactericidal
activity of dialysate with concentrations of cefonicid in the 1-
to 2-,ug/ml range against gram-positive pathogens as a pre-
lude to further clinical studies in patients with peritonitis.
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